In Conversation

Our job in LatAm is to ensure that the population in general, as well as healthcare providers and governments, understand the importance of diagnosing and treating…

Five of the 16 countries that together account for 85 percent of the growth of [GSK's emerging markets] region are from Latin America

The Mexican industry is going through a period of uncertainty, but I believe we will be in a better position in three or four years. Companies…

With many new governments in the region, we also expect to see changes to the healthcare environment in many of our countries.

... if high drug prices are the problem – and this administration says that a lot – then generics and biosimilars are the solution. I think…

... the Ichnos team has further accelerated our clinical stage pipeline in haematological malignancies to better position the firm and prepare it to host new investors…

I am a great believer in the US system and feel that there is a lot of misinformation about it.

The patient is ultimately the reason why we work in this industry, but historically the patient experience has tended to be sidelined

A lot of work is going on to increase funding for paediatric cancer and many centres – mine included – are not necessarily waiting around for…

If companies bring in the patient perspective from the beginning, the insights they gain could make their clinical trial process go quicker and create a better…

CAR-T, which was touted as a game-changing curative treatment, has been the answer for some patients, but not all

There is great potential for improvement if pharma companies can use agreed-upon standards for collecting data and for data interoperability. Even if the companies do not…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here